Vale; Wylie

Patent Applications and Registrations

Patent applications and USPTO patent grants for Vale; Wylie.The latest application filed is for "methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors".

Company Profile

0.11.12

Vale; Wylie - La Jolla CA US
Vale; Wylie - N/A
VALE; Wylie - US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Cripto antagonism of activin and TGF-b signaling Grant 9,546,210 - Vale , et al. January 17, 2	2017-01-17
Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors Grant 9,314,506 - Huising , et al. April 19, 2	2016-04-19
Methods For Increasing Insulin Secretion By Co-stimulation Of Corticotropin-releasing Factor Receptors App 20130109621 - HUISING; Mark ; et al.	2013-05-02
Isolated nucleic acids encoding soluble corticotropin releasing factor receptor type 2 (sCRFR2) polypeptides Grant 8,258,279 - Chen , et al. September 4, 2	2012-09-04
Cripto Antagonism Of Activin And Tgf-b Signaling App 20120141469 - Vale; Wylie ; et al.	2012-06-07
Cripto Antagonism Of Activin And Tgf-b Signaling App 20120088287 - Vale; Wylie ; et al.	2012-04-12
Cripto Antagonism Of Activin And Tgf-b Signaling App 20110009319 - Vale; Wylie ; et al.	2011-01-13
Cripto antagonism of activin and TGF-b signaling Grant 7,820,620 - Vale , et al. October 26, 2	2010-10-26
Compositions And Methods For The Inhibition Of Cripto / Grp78 Complex Formation And Signaling App 20100135904 - Gray; Peter C. ; et al.	2010-06-03
Activin-A mutants Grant 7,575,751 - Vale , et al. August 18, 2	2009-08-18
Isolated Soluble Corticotropin Releasing Factor Receptor Type 2 (scrfr2) App 20090117649 - CHEN; ALON ; et al.	2009-05-07
Isolated soluble corticotropin releasing factor receptor type 2 (sCRFR2) Grant 7,507,794 - Chen , et al. March 24, 2	2009-03-24
Urocortin-deficient mice and uses thereof Grant 7,488,865 - Lee , et al. February 10, 2	2009-02-10
Method of inhibiting the formation of inhibin/betaglycan complexes with an anti-betaglycan antibody Grant 7,455,839 - Vale , et al. November 25, 2	2008-11-25
Compositions and methods related to soluble G-protein coupled receptors (sGPCRs) App 20070042954 - Chen; Alon ; et al.	2007-02-22
Antagonism of TGF-beta superfamily receptor signaling App 20060008846 - Vale; Wylie ; et al.	2006-01-12
Cripto antagonism of activin and TGF-b signaling App 20050208045 - Vale, Wylie ; et al.	2005-09-22
Betaglycan as an inhibin receptor and uses thereof App 20040258689 - Vale, Wylie ; et al.	2004-12-23
Urocortin-deficient mice and uses thereof App 20040055028 - Lee, Kuo-Fen ; et al.	2004-03-18
Betaglycan as an inhibin receptor and uses thereof Grant 6,692,744 - Vale , et al. February 17, 2	2004-02-17
Betaglycan as an inhibin receptor and uses thereof App 20010049360 - Vale, Wylie ; et al.	2001-12-06
Corticotropin releasing factor receptor 1-deficient mice Grant 6,147,275 - Vale , et al. November 14, 2	2000-11-14

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.